ClinicalTrials.gg
RecruitingNCT04454203Updated Mar 23, 2026

Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension

A Phase 4 interventional study of Mepivacaine and Saline in Tourniquet Hypertension, Intraoperative Hypertension and Total Ankle Arthroplasty, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by Duke University · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Hypertension by Duke University — 8 open to participants now, 9 under way, none of them phase 3. Hypertension · Duke University.

Planned enrollment
29th of 37
40 · median 140
Started
2021
with 1 other
Phase 4
2 of 46
1 open now
Registered
32nd of 46
by date

Among the 46 studies in Hypertension by Duke University, this one is the 29th largest by planned enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2021, is one of 2 in phase 4, and was the 32nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

8 of the 46 studies in Hypertension by Duke University are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Hypertension by Duke University, or all of them as a file.
02

Study summary

The goal of this prospective randomized double-blind study is to determine if an ultrasound guided peri-arterial injection of local anesthetic (LA) superomedially the femoral artery via peripheral nerve catheter reverses ischemic hypertension associated with prolonged lower extremity tourniquet time.

Read the detailed description

This is a research study to find out if injection of numbing medication by the large artery going down your leg will improve high blood pressure caused by the tourniquet.

Depending on whether you enroll in this study, you may receive an injection of local anesthetic (numbing medication) or saline (salt water) by your femoral artery (the large artery going down your leg). This is to see how this injection impacts your blood pressure during surgery as the surgeons use a tourniquet (device that squeezes your leg) to help decrease the bleeding during surgery. Oftentimes the tourniquet causes your blood pressure to go up, but the numbing medication may help return your blood pressure close to its normal level. The rest of your anesthesia care, including other nerve blocks and general anesthetic, will be the same as it would be without participating in the study. You will be enrolled in this study for 24 hours.

03

Conditions studied

  • Tourniquet Hypertension
  • Intraoperative Hypertension
  • Total Ankle Arthroplasty
  • Ankle Fusion

Browse trials for

Keywords

  • Perifemoral
  • Tourniquet
  • Mepivacaine
  • Tourniquet Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients that will be included in the study are English speaking 18-75 year old ASA 1-3 patients undergoing total ankle arthroplasty.

Exclusion criteria

Exclusion Criteria:

  1. ASA 4 or 5
  2. Diagnosis of chronic pain
  3. Daily chronic opioid use (over 3 months of continuous opioid use).
  4. Inability to communicate pain scores or need for analgesia.
  5. Infection at the site of block placement
  6. Age under 18 years old or greater than 75 years old
  7. Pregnant women (as determined by standard of care day-of surgery urine bHCG)
  8. Intolerance/allergy to local anesthetics
  9. Weight \<50 kg
  10. Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
  11. Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance.
  12. Current or historical evidence of any disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Mepivacaine Block Group

    Infiltration of local anesthetic (mepivacaine) above and beside the femoral artery through a perineural catheter.

    Drug: Mepivacaine · Procedure: Perifemoral Injection of Local Anesthetic

  • Placebo comparator
    Saline Sham Group

    Infiltration of salt water (saline) above and beside the femoral artery through a perineural catheter.

    Drug: Saline · Procedure: Perifemoral Injection of Local Anesthetic

Interventions

  • An infiltration of mepivacaine superomedially to the femoral artery via perineural catheter.

    Also known as: Carbocaine

  • DrugSaline

    An infiltration of saline superomedially to the femoral artery via perineural catheter.

    Also known as: Salt water placebo

  • ProcedurePerifemoral Injection of Local Anesthetic

    Infiltration of mepivacaine superomedially to the formal artery via perineural catheter in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.

    Also known as: Femoral Periarterial Injection

  • ProcedurePerifemoral Injection of Local Anesthetic

    Infiltration of saline superomedially to the formal artery via perineural catheter that should NOT numb the nerves that contribute to tourniquet hypertension intraoperatively.

    Also known as: Femoral Periarterial Injection

06

What researchers measure

Primary outcomes

  1. Change in tourniquet hypertension as measured by systolic blood pressure

    Infiltrating study drug to reverse intraoperative tourniquet hypertension

    Time frame: From time of injection to 30 minutes after injection

Secondary outcomes

  1. Pain Scores (NRS11)

    The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable")

    Time frame: Perioperative start until 2 hours after admission to PACU

  2. Opioid consumption

    Perioperative opioid consumption as measured in oral morphine equivalents (OMEs)

    Time frame: Perioperative start until 2 hours after admission to PACU

  3. Quadriceps motor function

    Gross quadriceps motor function as measured by leg extension

    Time frame: 1 hour after extubation

07

Study locations

1 of 1 sites recruiting
  • Duke University Hospital
    Durham, North Carolina 27710, United States
    Recruiting
    • William M Bullock, MD, PhD · Contactwilliam.bullock@duke.edu · 919-681-6437
    • Amanda Kumar, MD · Contactamanda.kumar@duke.edu · 919-681-6437
    • Amanda Kumar, MD · Principal investigator
    • William M Bullock, MD, PhD · Sub investigator
    • Jeff C Gadsden, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2027, 71 months after the start.

Of 126 non-industry phase 4 interventional studies under Hypertension, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 71 months is above that.

Counting every sponsor, half of 161 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2020
First posted
Jul 1, 2020
StartActual
Feb 5, 2021
Primary completionEst.
Feb 1, 2027
CompletionEst.
Feb 3, 2027
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04454203
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Jul 1, 2020
Start date
Feb 5, 2021
Primary completion
Feb 1, 2027 (estimated)
Completion
Feb 3, 2027 (estimated)
Last update
Mar 23, 2026

Study contacts

William M Bullock, MD, PhD
Contact
william.bullock@duke.edu
919-681-6437
Jeff C Gadsden, MD
Contact
jeff.gadsden@duke.edu
919-681-6437
Amanda Kumar, MD, PhD
principal investigator · Duke University
William M Bullock, MD, PhD
study director · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mepivacaine

Start the discussion